Literature DB >> 2440026

Tenascin is a stromal marker for epithelial malignancy in the mammary gland.

E J Mackie, R Chiquet-Ehrismann, C A Pearson, Y Inaguma, K Taya, Y Kawarada, T Sakakura.   

Abstract

Tenascin is an extracellular matrix glycoprotein that is not present in the normal mature rat mammary gland. The distribution of tenascin was examined by immunohistochemistry in mammary tumors from carcinogen-treated and untreated rats, in virus-induced mammary tumors from mice, and in a variety of mammary gland lesions from humans. Tenascin was detectable in the stroma of the malignant but not of the benign tumors from all species. An inhibition ELISA, testing homogenates of rat tumors, confirmed that tenascin was present in malignant but not in benign tumors. Thus, tenascin was consistently found to be a stromal marker for epithelial malignancy in the mammary gland. It is concluded that tenascin may be involved in the interactions between the epithelial and mesenchyme-derived (stromal) components of the mammary gland, which are known to influence epithelial carcinogenesis in this organ.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2440026      PMCID: PMC305142          DOI: 10.1073/pnas.84.13.4621

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  20 in total

1.  The influence of the host and the neoplastic cell population on the collagen content of a tumor mass.

Authors:  P M GUILLINO; F H GRANTHAM
Journal:  Cancer Res       Date:  1963-05       Impact factor: 12.701

2.  Organ specificity in mesenchymal induction demonstrated in the embryonic development of the mammary gland of the mouse.

Authors:  K Kratochwil
Journal:  Dev Biol       Date:  1969-07       Impact factor: 3.582

3.  Monoclonal antibody localization in subcutaneous and intracranial human glioma xenografts: paired-label and imaging analysis.

Authors:  M A Bourdon; R E Coleman; R G Blasberg; D R Groothuis; D D Bigner
Journal:  Anticancer Res       Date:  1984 May-Jun       Impact factor: 2.480

4.  Sequential imaging of indium-111-labeled monoclonal antibody in human mammary tumors hosted in nude mice.

Authors:  B A Khaw; H W Strauss; S L Cahill; H R Soule; T Edgington; J Cooney
Journal:  J Nucl Med       Date:  1984-05       Impact factor: 10.057

5.  Increased content of Type V Collagen in desmoplasia of human breast carcinoma.

Authors:  S H Barsky; C N Rao; G R Grotendorst; L A Liotta
Journal:  Am J Pathol       Date:  1982-09       Impact factor: 4.307

6.  Lifetime dose-response relationships for mammary tumor induction by a single administration of N-methyl-N-nitrosourea.

Authors:  D L McCormick; C B Adamowski; A Fiks; R C Moon
Journal:  Cancer Res       Date:  1981-05       Impact factor: 12.701

7.  Accelerated mammary cancer development by fetal salivary mesenchyma isografted to adult mouse mammary epithelium.

Authors:  T Sakakura; Y Sakagami; Y Nishizuka
Journal:  J Natl Cancer Inst       Date:  1981-05       Impact factor: 13.506

8.  Polyester wax embedding and sectioning technique for immunohistochemistry.

Authors:  M Kusakabe; T Sakakura; Y Nishizuka; M Sano; A Matsukage
Journal:  Stain Technol       Date:  1984-05

9.  The prognostic value of the monoclonal antibodies HMFG1 and HMFG2 in breast cancer.

Authors:  N Berry; D B Jones; J Smallwood; I Taylor; N Kirkham; J Taylor-Papadimitriou
Journal:  Br J Cancer       Date:  1985-02       Impact factor: 7.640

10.  Chick myotendinous antigen. I. A monoclonal antibody as a marker for tendon and muscle morphogenesis.

Authors:  M Chiquet; D M Fambrough
Journal:  J Cell Biol       Date:  1984-06       Impact factor: 10.539

View more
  59 in total

1.  Protease-activated receptor-1 is upregulated in reactive stroma of primary prostate cancer and bone metastasis.

Authors:  Xiaotun Zhang; Wenbin Wang; Lawrence D True; Robert L Vessella; Thomas K Takayama
Journal:  Prostate       Date:  2009-05-15       Impact factor: 4.104

2.  Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts.

Authors:  Yasushi Kojima; Ahmet Acar; Elinor Ng Eaton; Kieran T Mellody; Christina Scheel; Ittai Ben-Porath; Tamer T Onder; Zhigang C Wang; Andrea L Richardson; Robert A Weinberg; Akira Orimo
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-01       Impact factor: 11.205

Review 3.  Targeting the tumour stroma to improve cancer therapy.

Authors:  Kenneth C Valkenburg; Amber E de Groot; Kenneth J Pienta
Journal:  Nat Rev Clin Oncol       Date:  2018-06       Impact factor: 66.675

Review 4.  Insidious changes in stromal matrix fuel cancer progression.

Authors:  Fayth L Miles; Robert A Sikes
Journal:  Mol Cancer Res       Date:  2014-01-22       Impact factor: 5.852

5.  The sequential expression of tenascin mRNA in epithelium and mesenchyme during feather morphogenesis.

Authors:  Richard P Tucker
Journal:  Rouxs Arch Dev Biol       Date:  1991-03

6.  Expression of tenascin in human gliomas: its relation to histological malignancy, tumor dedifferentiation and angiogenesis.

Authors:  M Higuchi; T Ohnishi; N Arita; S Hiraga; T Hayakawa
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

Review 7.  Three-dimensional context regulation of metastasis.

Authors:  Janine T Erler; Valerie M Weaver
Journal:  Clin Exp Metastasis       Date:  2008-09-24       Impact factor: 5.150

8.  Bipartite mRNA for chicken alpha-fibrinogen potentially encodes an amino acid sequence homologous to beta- and gamma-fibrinogens.

Authors:  L Weissbach; G Grieninger
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

9.  Differential expression of tenascin-C in the developing human lung: an immunohistochemical study.

Authors:  M Lambropoulou; V Limberis; N Koutlaki; M Simopoulou; D Ntanovasilis; G P Vandoros; P Tatsidou; I Kekou; I Koutsikogianni; N Papadopoulos
Journal:  Clin Exp Med       Date:  2009-07-21       Impact factor: 3.984

10.  Enhanced tenascin expression in cervical and vulvar koilocytotic lesions.

Authors:  O Tiitta; T Wahlström; J Paavonen; A Linnala; S Sharma; V E Gould; I Virtanen
Journal:  Am J Pathol       Date:  1992-10       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.